291 related articles for article (PubMed ID: 21362632)
1. Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model.
Levová K; Moserová M; Kotrbová V; Sulc M; Henderson CJ; Wolf CR; Phillips DH; Frei E; Schmeiser HH; Mares J; Arlt VM; Stiborová M
Toxicol Sci; 2011 May; 121(1):43-56. PubMed ID: 21362632
[TBL] [Abstract][Full Text] [Related]
2. Role of cytochromes P450 in metabolism of carcinogenic aristolochic acid I: evidence of their contribution to aristolochic acid I detoxication and activation in rat liver.
Stiborova M; Mares J; Levova K; Pavlickova J; Barta F; Hodek P; Frei E; Schmeiser HH
Neuro Endocrinol Lett; 2011; 32 Suppl 1():121-30. PubMed ID: 22167220
[TBL] [Abstract][Full Text] [Related]
3. Role of P450 1A1 and P450 1A2 in bioactivation versus detoxication of the renal carcinogen aristolochic acid I: studies in Cyp1a1-/-, Cyp1a2-/-, and Cyp1a1/1a2-/- mice.
Arlt VM; Levová K; Bárta F; Shi Z; Evans JD; Frei E; Schmeiser HH; Nebert DW; Phillips DH; Stiborová M
Chem Res Toxicol; 2011 Oct; 24(10):1710-9. PubMed ID: 21932800
[TBL] [Abstract][Full Text] [Related]
4. Knockout and humanized mice as suitable tools to identify enzymes metabolizing the human carcinogen aristolochic acid.
Stiborová M; Frei E; Arlt VM; Schmeiser HH
Xenobiotica; 2014 Jan; 44(2):135-45. PubMed ID: 24152141
[TBL] [Abstract][Full Text] [Related]
5. Human cytochromes P450 1A1 and 1A2 participate in detoxication of carcinogenic aristolochic acid.
Sistkova J; Hudecek J; Hodek P; Frei E; Schmeiser HH; Stiborova M
Neuro Endocrinol Lett; 2008 Oct; 29(5):733-7. PubMed ID: 18987598
[TBL] [Abstract][Full Text] [Related]
6. The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers.
Stiborova M; Frei E; Arlt VM; Schmeiser HH
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):5-11. PubMed ID: 19365519
[TBL] [Abstract][Full Text] [Related]
7. Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2.
Stiborová M; Levová K; Bárta F; Shi Z; Frei E; Schmeiser HH; Nebert DW; Phillips DH; Arlt VM
Toxicol Sci; 2012 Feb; 125(2):345-58. PubMed ID: 22086975
[TBL] [Abstract][Full Text] [Related]
8. Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer.
Stiborová M; Frei E; Hodek P; Wiessler M; Schmeiser HH
Int J Cancer; 2005 Jan; 113(2):189-97. PubMed ID: 15386410
[TBL] [Abstract][Full Text] [Related]
9. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
[TBL] [Abstract][Full Text] [Related]
10. NAD(P)H:quinone oxidoreductase expression in Cyp1a-knockout and CYP1A-humanized mouse lines and its effect on bioactivation of the carcinogen aristolochic acid I.
Levova K; Moserova M; Nebert DW; Phillips DH; Frei E; Schmeiser HH; Arlt VM; Stiborova M
Toxicol Appl Pharmacol; 2012 Dec; 265(3):360-7. PubMed ID: 22982977
[TBL] [Abstract][Full Text] [Related]
11. Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2.
Stiborová M; Frei E; Wiessler M; Schmeiser HH
Chem Res Toxicol; 2001 Aug; 14(8):1128-37. PubMed ID: 11511187
[TBL] [Abstract][Full Text] [Related]
12. The influence of dicoumarol on the bioactivation of the carcinogen aristolochic acid I in rats.
Stiborová M; Levová K; Bárta F; Šulc M; Frei E; Arlt VM; Schmeiser HH
Mutagenesis; 2014 May; 29(3):189-200. PubMed ID: 24598128
[TBL] [Abstract][Full Text] [Related]
13. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice.
Arlt VM; Stiborová M; Henderson CJ; Thiemann M; Frei E; Aimová D; Singh R; Gamboa da Costa G; Schmitz OJ; Farmer PB; Wolf CR; Phillips DH
Carcinogenesis; 2008 Mar; 29(3):656-65. PubMed ID: 18204078
[TBL] [Abstract][Full Text] [Related]
14. A Mechanism of O-Demethylation of Aristolochic Acid I by Cytochromes P450 and Their Contributions to This Reaction in Human and Rat Livers: Experimental and Theoretical Approaches.
Stiborová M; Bárta F; Levová K; Hodek P; Schmeiser HH; Arlt VM; Martínek V
Int J Mol Sci; 2015 Nov; 16(11):27561-75. PubMed ID: 26593908
[TBL] [Abstract][Full Text] [Related]
15. Induction of cytochromes P450 1A1 and 1A2 suppresses formation of DNA adducts by carcinogenic aristolochic acid I in rats in vivo.
Dračínská H; Bárta F; Levová K; Hudecová A; Moserová M; Schmeiser HH; Kopka K; Frei E; Arlt VM; Stiborová M
Toxicology; 2016 Feb; 344-346():7-18. PubMed ID: 26845733
[TBL] [Abstract][Full Text] [Related]
16. The binding of aristolochic acid I to the active site of human cytochromes P450 1A1 and 1A2 explains their potential to reductively activate this human carcinogen.
Stiborová M; Sopko B; Hodek P; Frei E; Schmeiser HH; Hudecek J
Cancer Lett; 2005 Nov; 229(2):193-204. PubMed ID: 16125300
[TBL] [Abstract][Full Text] [Related]
17. Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1.
Jerabek P; Martinek V; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():25-32. PubMed ID: 23353840
[TBL] [Abstract][Full Text] [Related]
18. Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase.
Stiborová M; Frei E; Sopko B; Sopková K; Marková V; Lanková M; Kumstýrová T; Wiessler M; Schmeiser HH
Carcinogenesis; 2003 Oct; 24(10):1695-703. PubMed ID: 12869422
[TBL] [Abstract][Full Text] [Related]
19. Enzymes metabolizing aristolochic acid and their contribution to the development of aristolochic acid nephropathy and urothelial cancer.
Stiborová M; Martínek V; Frei E; Arlt VM; Schmeiser HH
Curr Drug Metab; 2013 Jul; 14(6):695-705. PubMed ID: 23701164
[TBL] [Abstract][Full Text] [Related]
20. Exposure to benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null (HRN) and P450 Reductase Conditional Null (RCN) mice: Detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and 32P-postlabelling.
Arlt VM; Poirier MC; Sykes SE; John K; Moserova M; Stiborova M; Wolf CR; Henderson CJ; Phillips DH
Toxicol Lett; 2012 Sep; 213(2):160-6. PubMed ID: 22759596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
